REALIZING THE POSSIBLE
Advancing technology to turn theories into medical realities.
Treatment is more successful the earlier cancer is detected. Unfortunately, today, cancer screening is full of challenges:
- Tests are available for limited cancers
- Procedures can be invasive (i.e. colonoscopies)
- Hard for patients to follow through
- Tests may not be suitable for the clinical need
Patients and the medical community have been eager for a future where accuracy and efficiency and can be achieved in a single non-invasive test. By combining deep data science with a new approach in genomic sequencing, Quantgene is making this possibility a reality.
SURVIVAL & STAGE OF DIAGNOSIS
10 Year Survival for 8 Types of Cancer Combined
THE PROMISE OF CELL-FREE DNA
All tumors shed cell-free DNA (cfDNA) at the earliest stages of growth. These cfDNA fragments can be detected through liquid biopsy in a small blood sample.
For sometime, cell-free DNA in the blood has been recognized as a highly precise and accurate biomarker of cancer. However, to-date, no available technology has been able to fully unlock this approach for early detection.
UNLOCKING cfDNA WITH QUANTUM ARRAY
Quantgene’s QUANTUM ARRAY, is the first fully-integrated technology stack to combine lab chemistry, data and machine learning processes in one seamless system. This engine allows us to detect a single cfDNA molecule of multiple types of cancers from one blood draw.
The full-integration of the QUANTUM ARRAY tech stack also enables:
QUANTUM ARRAY unlocks full visibility of every data point from clinical reports all the way down to lab chemistry. The result is confidence in the accuracy of our results.
Rapid and continuous improvement
QUANTUM ARRAY is a system that continues to learn and improve with every sample to:
- Continuously improve clinical accuracy
- Take our capabilities to more forms of cancers and other clinical conditions